DiaMedica Therapeutics to Report Second Quarter 2023 Financial Results and Provide a Business Update August 15, 2023
08 Agosto 2023 - 9:32AM
Business Wire
DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage
biopharmaceutical company currently focused on developing
recombinant KLK1 (DM199) for the treatment of acute ischemic
stroke, announced today that its second quarter 2023 financial
results will be released after the markets close on Monday, August
14th. DiaMedica will host a live conference call on Tuesday, August
15th at 7:00 AM Central Time to provide a business update and
discuss financial results.
Conference Call details:
Date:
Tuesday, August 15, 2023
Time:
7:00 AM CT / 8:00 AM ET
Web access:
https://app.webinar.net/DnqEQYkbk6Z
Dial In:
(877) 550-1858
Conference ID:
2125#
Interested parties may access the conference call by dialing in
or listening to the simultaneous webcast. Listeners should log on
to the website or dial in 15 minutes prior to the call. The webcast
will remain available for play back on our website, under investor
relations - events and presentations, following the earnings call
and for 12 months thereafter. A telephonic replay of the conference
call will be available until August 22, 2023, by dialing (800)
645-7964 (US Toll Free) and entering the replay passcode:
2125#.
About DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc. is a clinical stage
biopharmaceutical company committed to improving the lives of
people suffering from serious diseases with a focus on acute
ischemic stroke. DiaMedica’s lead candidate DM199 is the first
pharmaceutically active and clinically studied recombinant
(synthetic) form of the KLK1 protein, an established therapeutic
modality in Asia for the treatment of acute ischemic stroke and
other vascular diseases. For more information visit our website at
www.diamedica.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230808344534/en/
Scott Kellen Chief Financial Officer Phone: (763) 496-5118
skellen@diamedica.com
Paul Papi Corporate Communications Phone: 617-899-5941
ppapi@diamedica.com
DiaMedica Therapeutics (NASDAQ:DMAC)
Gráfico Histórico do Ativo
De Dez 2024 até Jan 2025
DiaMedica Therapeutics (NASDAQ:DMAC)
Gráfico Histórico do Ativo
De Jan 2024 até Jan 2025
